Physician profile
David Sanchez
NPI 1386359701
$7,822.67
in general payments reported to CMS, 2019-2025
21 companies · $4,021 in 2025
The $4,021 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $637 · 2024: $3,165 · 2025: $4,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,465 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,464.75 |
| Education | $357.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,346.17 | 2023-2025 | |
| Janssen Biotech, INC. | $879.28 | 2024-2025 | Tremfya |
| Amgen INC. | $830.98 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $784.71 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $700.20 | 2024-2025 | |
| Incyte Corporation | $616.69 | 2024-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $597.66 | 2023-2025 | Ilumya, Winlevi |
| Dermavant Sciences, INC. | $363.37 | 2023-2024 | Vtama |
| Lilly USA, LLC | $359.83 | 2024 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $306.30 | 2024-2025 | Nemluvio |
| Botanix Sb INC | $169.75 | 2025 | Sofdra |
| Genzyme Corporation | $169.73 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $162.57 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $155.62 | 2024-2025 | Sotyktu |
| Pfizer INC. | $106.00 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.68 | 2024 | Duobrii, Siliq |
| Biofrontera INC. | $99.62 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $25.95 | 2024 | Adbry |
| Lundbeck LLC | $19.63 | 2024 | Rexulti |
| Almirall LLC | $16.12 | 2025 | Klisyri |
| Organon LLC | $7.81 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.